Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy

Ähnliche Einträge

• Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis
  von: Zhen Jia, et al.
  Veröffentlicht: (2026)
• Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
  von: Li Li, et al.
  Veröffentlicht: (2024)
• The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer‐bearing mice and patients
  von: Mingtao Liu, et al.
  Veröffentlicht: (2024)
• Efficacy of immune checkpoint inhibitors in advanced non‐small cell lung cancer patients with KRAS mutations: A network meta‐analysis
  von: Lin Zhang, et al.
  Veröffentlicht: (2024)
• Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice
  von: Xiaojie Huang, et al.
  Veröffentlicht: (2024)